Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Neoadjuvant SBRT Plus Cemiplimab Results in Pathologic Responses in Resectable HCC

January 5th 2024

Significant tumor necrosis greater than 70% occurred in 3 patients with resectable hepatocellular carcinoma following neoadjuvant treatment with low-dose stereotactic body radiation therapy and cemiplimab-rwlc and adjuvant cemiplimab.

The Power of Patient Connection

January 4th 2024

Patient care begins with the patient, and Deb Schrag, MD, MPH, has spent her career keeping them the main focus of improving oncologic outcomes.

Dr Kim on a Case Study of a Patient With HCC

January 3rd 2024

Richard Kim, MD, discusses a case study of a patient who presented with hepatocellular carcinoma, detailing the steps that were taken upon diagnosis.

FDA Grants Fast Track Status to Aglatimagene Besadenovec Plus Valacyclovir for Pancreatic Cancer

January 2nd 2024

The FDA has granted fast track designation to aglatimagene besadenovec plus valacyclovir for use as a potential therapeutic option in patients with pancreatic ductal adenocarcinoma.

Sugemalimab Plus Chemo Receives Approval in China for Esophageal Squamous Cell Carcinoma

January 2nd 2024

The National Medical Products Administration of China has approved sugemalimab paired with fluorouracil and platinum-based chemotherapy for use in the frontline treatment of patients with unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma.

Future Directions in the Management of Hepatocellular Carcinoma

January 2nd 2024

To close, Dr. Saeed and Dr. Singal share their excitement for the future landscape, emerging agents and treatment strategies for patients with HCC.

Revolutionizing GI Oncology Around the Globe

December 28th 2023

Eileen M. O’Reilly, MD, traveled a serendipitous journey from Ireland to the United States, where she has made her mark on transforming gastrointestinal cancer treatment.

What Fellows Need to Know: Key Takeaways From ESMO 2023

December 26th 2023

The 2023 ESMO Congress took place October 20 to 24 in Madrid, Spain, with global perspectives on groundbreaking data. We break down some of the key highlights from the annual meeting that oncology fellows should absorb, and apply to practice, as soon as possible.

Additional Data Updates from AASLD 2023

December 26th 2023

Drs Saeed and Singal discuss additional data presented at AASLD 2023 related to frontline systemic therapies and emerging combinations in unresectable HCC.

Real-World Data and Impact on Treatment Selection in uHCC

December 26th 2023

Expert oncologists review real-world data and discuss the impact on treatment selection in uHCC.

European Commission Approves New Frontline Indications for Pembrolizumab Plus Chemo in Select GI Cancers

December 21st 2023

The European Commission has approved new indications for pembrolizumab in combination with chemotherapy in select patients with gastric or gastroesophageal adenocarcinoma and select patients with biliary tract cancer.

Dr Shiu on the FDA Approval of Pembrolizumab Plus Chemotherapy in Advanced HER2– Gastric/GEJ Adenocarcinoma

December 19th 2023

Kai-Keen Shiu, MD, discusses the significance of the FDA approval of pembrolizumab in combination with fluoropyrimidine- and platinum-containing chemotherapy as a first-line treatment in patients with locally advanced, unresectable or metastatic, HER2-negative gastric or gastroesophageal junction adenocarcinoma.

Efficacy and Safety Outcomes in Combination Immunotherapy for uHCC

December 19th 2023

An expert analysis in data surrounding treatment outcomes in combination regimens, noting immune-mediate adverse events and overall impact on treatment response.

AASLD 2023 Updates: HIMALAYA Trial for uHCC

December 19th 2023

Dr. Saeed outlines the use of combination tremelimumab plus durvalumab in uHCC, discussing updates from the HIMALAYA trial presented at AASLD 2023.

Shitara and Xu Discuss Potential FDA Approval of Zolbetuximab in CLDN18.2+ Gastric/GEJ Adenocarcinoma

December 15th 2023

Rui-Hua Xu, MD, PhD, and Kohei Shitara, MD, expand on the advantages of targeting CLDN18.2 with zolbetuximab in gastric/GEJ adenocarcinoma and key efficacy data from the GLOW and SPOTLIGHT trials in support of zolbetuximab’s potential FDA approval.

Intrahepatic Cholangiocarcinoma Overview

December 14th 2023

Medical experts discuss the pathology of intrahepatic cholangiocarcinoma.

Atezolizumab plus Bevacizumab in the Treatment of Unresectable HCC

December 12th 2023

A comprehensive review of clinical data of atezolizumab plus bevacizumab for the treatment of unresectable HCC.

The Evolving Landscape of Hepatocellular Carcinoma

December 12th 2023

Anwaar Saeed, MD, and Amit Singal, MD, discuss the evolving treatment landscape for hepatocellular carcinoma, highlighting FDA approvals and the utility of clinical biomarkers.

Closing Thoughts on Evolving Antibody-Drug Conjugate Landscape

December 1st 2023

The expert panel concludes the program with key takeaways and closing thoughts on the evolving antibody-drug conjugate space.

Educating Community Specialists on Evolving Treatment Landscape

November 24th 2023

Experts in breast, lung, and gastric malignancies provide insights on multidisciplinary care in oncology and educating community specialists.